[go: up one dir, main page]

DK3748358T3 - Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid - Google Patents

Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid Download PDF

Info

Publication number
DK3748358T3
DK3748358T3 DK20182629.4T DK20182629T DK3748358T3 DK 3748358 T3 DK3748358 T3 DK 3748358T3 DK 20182629 T DK20182629 T DK 20182629T DK 3748358 T3 DK3748358 T3 DK 3748358T3
Authority
DK
Denmark
Prior art keywords
defibrotid
efficacy
cell
determining
based method
Prior art date
Application number
DK20182629.4T
Other languages
English (en)
Inventor
Terenzio Ignoni
Vijay Kumar
Claudio Verga
Original Assignee
Gentium S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52000693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3748358(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentium S R L filed Critical Gentium S R L
Application granted granted Critical
Publication of DK3748358T3 publication Critical patent/DK3748358T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK20182629.4T 2014-11-27 2015-11-23 Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid DK3748358T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195277.0A EP3026122A1 (en) 2014-11-27 2014-11-27 Cellular-based method for determining the potency of defibrotide
EP15798418.8A EP3120153B1 (en) 2014-11-27 2015-11-23 Cellular-based method for determining the potency of defibrotide

Publications (1)

Publication Number Publication Date
DK3748358T3 true DK3748358T3 (da) 2024-02-26

Family

ID=52000693

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15798418.8T DK3120153T3 (da) 2014-11-27 2015-11-23 Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid
DK20182629.4T DK3748358T3 (da) 2014-11-27 2015-11-23 Cellebaseret fremgangsmåde til bestemmelse af virkningsgraden af defibrotid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15798418.8T DK3120153T3 (da) 2014-11-27 2015-11-23 Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid

Country Status (19)

Country Link
US (3) US10393731B2 (da)
EP (4) EP3026122A1 (da)
JP (3) JP6700276B2 (da)
KR (2) KR102421677B1 (da)
CN (1) CN107109458B (da)
AU (2) AU2015352743B2 (da)
BR (1) BR112017011012B1 (da)
CA (1) CA2968608C (da)
DK (2) DK3120153T3 (da)
ES (2) ES2972368T3 (da)
FI (1) FI3748358T3 (da)
IL (2) IL252484B (da)
MX (2) MX390823B (da)
PL (1) PL3120153T3 (da)
PT (1) PT3120153T (da)
RU (1) RU2729628C2 (da)
SG (1) SG11201704015RA (da)
WO (1) WO2016083297A1 (da)
ZA (1) ZA201703385B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2694239T3 (es) 2010-11-12 2018-12-19 Gentium S.R.L. Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD)
KR20150044877A (ko) 2012-06-22 2015-04-27 젠티엄 에스피에이 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
CN111796086A (zh) * 2020-07-03 2020-10-20 同济大学 一种个人护理品急慢性剂量-效应关系表征方法
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
DE2812943C3 (de) 1978-03-23 1981-05-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren und Reagens zur Bestimmung der biologischen Aktivität von Heparin im Plasma
US4853221A (en) 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1170215B (it) 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1206341B (it) 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US4693134A (en) 1985-06-20 1987-09-15 Excelermatic Inc. High-powered vehicle drive train
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5231006A (en) 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US4753221A (en) 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
IT1223322B (it) 1987-10-23 1990-09-19 Crinos Industria Farmaco Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso
JP2907447B2 (ja) 1988-08-24 1999-06-21 中外製薬株式会社 抗血栓剤
IT1231509B (it) 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US5624912A (en) 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH08127539A (ja) 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
WO1996016987A1 (en) 1994-11-30 1996-06-06 Chugai Seiyaku Kabushiki Kaisha Thrombocytotic factor
DE69733694T2 (de) 1996-07-10 2006-07-06 Muramatsu, Takashi, Nagoya Verwendung von proteinen aus der mk familie als hämatopoietischer faktor
WO1998048843A1 (en) 1997-04-28 1998-11-05 Arsinur Burcoglu Method of treating hiv infection and related secondary infections thereof
AU8125098A (en) 1997-05-30 1998-12-30 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
GB9719161D0 (en) 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
CA2377385A1 (en) 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
ATE311907T1 (de) 1999-06-08 2005-12-15 Gentium Spa Anwendung von komplexen von kationischen liposomen und polydeoxyribonukleotiden wie arzneimitteln
US8771663B2 (en) 2000-04-18 2014-07-08 Gentium Spa Formulation having mobilising activity
EP1147777A1 (en) 2000-04-18 2001-10-24 Crinos Industria Farmacobiologica S.p.A. Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
WO2002057414A2 (en) 2000-10-20 2002-07-25 Expression Diagnostics, Inc. Leukocyte expression profiling
WO2002045431A2 (en) * 2000-11-28 2002-06-06 The University Of Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
HUP0700079A2 (en) 2000-12-29 2007-05-02 Savient Pharmaceuticals Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
US7514414B2 (en) 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
WO2003078960A2 (en) 2002-03-11 2003-09-25 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US20050215498A1 (en) 2002-05-31 2005-09-29 Guenther Eissner Method for the protection of endothelial and epithclial cells during chemotherapy
CA2487171A1 (en) 2002-05-31 2003-12-11 Klinikum Der Universitat Regensburg Method for the protection of endothelial and epithelial cells during chemotherapy
AU2003263764A1 (en) 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
JP4483581B2 (ja) 2002-08-06 2010-06-16 東レ株式会社 腎疾患治療又は予防剤及び腎疾患の診断方法
US20050196382A1 (en) 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
US7723127B2 (en) * 2005-03-03 2010-05-25 Novx Systems Inc. Immunoassay with extended dynamic range
JP2008531647A (ja) 2005-03-03 2008-08-14 ゲンチウム エスピーエー 抗腫瘍作用を有する製剤
WO2006119619A1 (en) 2005-05-06 2006-11-16 Replicor Inc. Oligonucleotides inhibiting cell proliferation
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
US20090023158A1 (en) * 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase
EP2103689A1 (en) 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
JP2011522515A (ja) * 2008-04-10 2011-08-04 マサチューセッツ インスティテュート オブ テクノロジー 癌幹細胞を標的とする薬剤を同定する方法およびその使用
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ES2694239T3 (es) 2010-11-12 2018-12-19 Gentium S.R.L. Defibrótido para su uso en profilaxis y/o tratamiento de la enfermedad de Injerto contra huésped (GVHD)
KR20150044877A (ko) 2012-06-22 2015-04-27 젠티엄 에스피에이 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide

Also Published As

Publication number Publication date
SG11201704015RA (en) 2017-06-29
ES2831834T3 (es) 2021-06-09
US20200057051A1 (en) 2020-02-20
RU2729628C2 (ru) 2020-08-11
RU2017122187A (ru) 2018-12-28
CN107109458A (zh) 2017-08-29
IL252484A0 (en) 2017-07-31
EP3120153B1 (en) 2020-08-19
MX2022003399A (es) 2022-04-18
PL3120153T3 (pl) 2021-02-08
EP4368990A2 (en) 2024-05-15
KR102421677B1 (ko) 2022-07-18
KR20220104070A (ko) 2022-07-25
IL277068A (en) 2020-10-29
JP2020058360A (ja) 2020-04-16
EP3026122A1 (en) 2016-06-01
MX2017006970A (es) 2018-03-01
CN107109458B (zh) 2021-10-26
EP3748358B1 (en) 2023-12-27
AU2020250225A1 (en) 2020-11-05
WO2016083297A1 (en) 2016-06-02
AU2015352743A1 (en) 2017-06-08
IL277068B (en) 2021-10-31
EP3120153A1 (en) 2017-01-25
CA2968608C (en) 2023-09-05
NZ731825A (en) 2024-02-23
KR20170094790A (ko) 2017-08-21
US20170322199A1 (en) 2017-11-09
BR112017011012B1 (pt) 2024-01-16
US10393731B2 (en) 2019-08-27
AU2020250225B2 (en) 2022-06-30
AU2015352743B2 (en) 2020-10-15
FI3748358T3 (fi) 2024-02-14
DK3120153T3 (da) 2020-11-09
MX390823B (es) 2025-03-21
ZA201703385B (en) 2018-08-29
JP2022160596A (ja) 2022-10-19
PT3120153T (pt) 2020-10-20
US20230194502A1 (en) 2023-06-22
RU2017122187A3 (da) 2019-01-17
EP4368990A3 (en) 2024-08-07
JP6700276B2 (ja) 2020-05-27
BR112017011012A2 (pt) 2018-02-14
IL252484B (en) 2020-09-30
CA2968608A1 (en) 2016-06-02
JP2017535277A (ja) 2017-11-30
EP3748358A1 (en) 2020-12-09
ES2972368T3 (es) 2024-06-12

Similar Documents

Publication Publication Date Title
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3538864T3 (da) Mikrotom
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3198035T3 (da) Fremgangsmåder til forudsigelse af medicinrespons
DK3192902T3 (da) Fremgangsmåde til fremstilling af graphenholdige viscosefibre
DK3346961T3 (da) Anordning til stomi
LT3303334T (lt) Tirozinkinazės inhibitoriai
IL249981A0 (en) Method
CL2016002129A1 (es) Compuestos de azolina
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3940352T3 (da) Fremgangsmåde til diagnosticering af vægte
DK3442972T3 (da) Bromdomænehæmmere
DK3201361T3 (da) Fremgangsmåder til kvantificering af cellefrit DNA
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3122444T3 (da) Fremgangsmåde til fremstilling af membraner
DK3344805T3 (da) Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
DK3125898T3 (da) Farmakofor til trail-induktion
DK3314010T3 (da) Fremgangsmåde til detektering af kromosomaberrationer
DK3001176T3 (da) Sensor til overvågning af korrosion
DK3128910T3 (da) Fremgangsmåde til bestemmelse af tværsnitsarealet og voluminet af et objekt
DK3487443T3 (da) Fremgangsmåde til opmåling af en implantat-implantat-situation
DK2904972T3 (da) Indretning til bestemmelse af dødt cochlear-område
DK3114235T3 (da) Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases